Form 4: Karyopharm Therapeutics SVP Michael Mano Sells Shares to Cover Tax Obligations

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, sold shares of common stock on February 29, 2024, and March 1, 2024, to cover withholding tax liabilities.

Summary

• Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics Inc., sold shares of the company's common stock on February 29, 2024, and March 1, 2024.
• The sales were executed to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and performance-based restricted stock units.
• On February 29, 2024, 16,973 shares were sold at a weighted average price of $1.17.
• On March 1, 2024, 3,576 shares were sold at a price of $1.2.
• These transactions were conducted under a pre-arranged automatic sale instruction plan adopted on May 16, 2022.
• Following these transactions, Mano directly owns 277,852 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to compensation and tax obligations. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The stock sales by a company officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the overall market sentiment.

Key Dates